Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.83 |
| ▸ | TCF4 | P15884 | 3/20 | 0.83 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.83 |
| ▸ | CLPP | Q16740 | 6/20 | 0.48 |
| ▸ | TCF7 | P36402 | 2/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15837013 | 1.00 | CTNNB1 (0.83) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL15960522 | 1.00 | CTNNB1 (0.83) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL1592761 | 0.99 | CTNNB1 (0.82) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL1560092 | 0.94 | CTNNB1 (0.74) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| Phosphoric Acid SCHEMBL25384064 | 0.91 | CTNNB1 (0.69) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL30674063 | 0.91 | CTNNB1 (1.00) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL1591981 | 0.91 | CTNNB1 (1.00) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL29372747 | 0.91 | CTNNB1 (1.00) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL16860492 | 0.91 | CTNNB1 (0.77) | CTNNB1TCF4CREBBPCLPPTCF7 | |
| SCHEMBL30671531 | 0.91 | CTNNB1 (1.00) | CTNNB1TCF4CREBBPCLPPTCF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266212-A1 | PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS | PRISM PHARMA CO., LTD. (JP) | 2017-09-21 | — | — | US | claimed |
| US-20160263131-A1 | TREATMENT OF HEPATIC FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2016-09-15 | — | — | US | claimed |
| US-20160244453-A1 | TREATMENT OF VIRAL AND INFECTIOUS DISEASES USING AN INHIBITOR OF CBP/CATENIN | PRISM PHARMA CO., LTD. (JP) | 2016-08-25 | — | — | US | claimed |
| EP-3057590-A2 | TREATMENT OF HEPATIC FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | Kouji, Hiroyuki (JP) | 2016-08-24 | — | — | EP | claimed |
| US-20160166578-A1 | METHOD FOR TREATING TYPE I AND TYPE II DIABETES | PRISM PHARMA CO., LTD. (JP) | 2016-06-16 | — | — | US | claimed |
| US-20160166577-A1 | TREATMENT OF PULMONARY FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | PRISM PHARMA CO., LTD. (JP) | 2016-06-16 | — | — | US | claimed |
| US-9193734-B2 | Alpha helix mimetics and methods relating thereto | PRISM PHARMA CO., LTD. (JP) | 2015-11-24 | — | — | US | claimed |
| US-20150306115-A1 | PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS | PRISM PHARMA CO., LTD. (JP) | 2015-10-29 | — | — | US | claimed |
| EP-2932977-A1 | PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS | Prism Pharma Co., Ltd. (JP) | 2015-10-21 | — | — | EP | claimed |
| US-20150284393-A1 | METHODS FOR TREATING EYE DISORDERS | PRISM PHARMA CO., LTD. (JP) | 2015-10-08 | — | — | US | claimed |
| WO-2015056104-A2 | TREATMENT OF HEPATIC FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2015-04-23 | — | — | WO | claimed |
| WO-2014061826-A1 | TREATMENT OF HYPERPROLIFERATIVE AND PRE-CANCEROUS SKIN DISEASES USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2014-04-24 | — | — | WO | claimed |
| WO-2014061825-A1 | TREATMENT OF VIRAL AND INFECTIOUS DISEASES USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2014-04-24 | — | — | WO | claimed |
| WO-2014061828-A1 | TREATMENT OF SCLERODERMA USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2014-04-24 | — | — | WO | claimed |
| WO-2014061823-A1 | METHOD FOR TREATING TYPE I AND TYPE II DIABETES | KOUJI HIROYUKI (JP) | 2014-04-24 | — | — | WO | claimed |
| WO-2014061824-A1 | METHODS FOR TREATING EYE DISORDERS | KOUJI HIROYUKI (JP) | 2014-04-24 | — | — | WO | claimed |
| WO-2014061827-A1 | TREATMENT OF PULMONARY FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | KOUJI HIROYUKI (JP) | 2014-04-24 | — | — | WO | claimed |
| EP-2650295-A1 | Alpha helix mimetics and methods relating thereto | Prism Biolab Corporation (JP) | 2013-10-16 | — | — | EP | claimed |
| US-20130267482-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM PHARMA CO., LTD. (JP) | 2013-10-10 | — | — | US | claimed |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2011-04-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306115-A1 | PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS | CREBBP, PYGL, CTNNBL1 | CTNNB1 4/4885TCF4 94/4885CREBBP 1/4885 |
| US-20130267482-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | CTNNB1 416/4885TCF4 572/4885CREBBP 569/4885 |
| US-20160166578-A1 | METHOD FOR TREATING TYPE I AND TYPE II DIABETES | IAPP, CTNNB1, CTNNBL1 | CTNNB1 2/4885TCF4 82/4885CREBBP 497/4885 |
| US-20160263131-A1 | TREATMENT OF HEPATIC FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | CTNNBL1, CTNNB1, CREBBP | CTNNB1 2/4885TCF4 68/4885CREBBP 3/4885 |
| US-20160166577-A1 | TREATMENT OF PULMONARY FIBROSIS USING AN INHIBITOR OF CBP/CATENIN | CTNNB1, CTNNBL1, CTNNA1 | CTNNB1 1/4885TCF4 39/4885CREBBP 6/4885 |
| US-20170266212-A1 | PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS | PYGL, CREBBP, CTNNBL1 | CTNNB1 4/4885TCF4 78/4885CREBBP 2/4885 |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | CTNNB1 416/4885TCF4 572/4885CREBBP 569/4885 |
| US-20160244453-A1 | TREATMENT OF VIRAL AND INFECTIOUS DISEASES USING AN INHIBITOR OF CBP/CATENIN | CTNNB1, CTNNBL1, CTNNA1 | CTNNB1 1/4885TCF4 48/4885CREBBP 6/4885 |
| US-20150284393-A1 | METHODS FOR TREATING EYE DISORDERS | CRYAB, EYA3, UACA | CTNNB1 4/4885TCF4 1029/4885CREBBP 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.